Fang Lei

List of Publications by Year
in descending order

24 papers	3,628 citations	623734 14 h-index	610901 24 g-index
24 all docs	24 docs citations	24 times ranked	8261 citing authors

#	Article	IF	Citations
1	High Remnant Cholesterol Level Potentiates the Development of Hypertension. Frontiers in Endocrinology, 2022, 13, 830347.	3.5	20
2	Projection of global burden and risk factors for aortic aneurysm â€" timely warning for greater emphasis on managing blood pressure. Annals of Medicine, 2022, 54, 553-564.	3.8	16
3	Global death burden and attributable risk factors of peripheral artery disease by age, sex, SDI regions, and countries from 1990 to 2030: Results from the Global Burden of Disease study 2019. Atherosclerosis, 2022, 347, 17-27.	0.8	7
4	Association Between Lipid Profiles and Left Ventricular Hypertrophy: New Evidence from a Retrospective Study. Chinese Medical Sciences Journal, 2022, 37, 103.	0.4	3
5	Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. American Journal of Physiology - Cell Physiology, 2022, 323, C630-C639.	4.6	10
6	REPLY:. Hepatology, 2021, 73, 470-471.	7.3	4
7	Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med, 2021, 2, 38-48.e2.	4.4	47
8	Extracorporeal Membrane Oxygenation Therapy for Critically Ill Coronavirus Disease 2019 Patients in Wuhan, China: A Retrospective Multicenter Cohort Study. Current Medical Science, 2021, 41, 1-13.	1.8	14
9	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metabolism, 2021, 33, 258-269.e3.	16.2	87
10	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. Med, 2021, 2, 435-447.e4.	4.4	20
11	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. Current Medical Research and Opinion, 2021, 37, 917-927.	1.9	11
12	Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metabolism, 2021, 33, 1943-1956.e2.	16.2	59
13	Heavy Disease Burden of High Systolic Blood Pressure During 1990-2019: Highlighting Regional, Sex, and Age Specific Strategies in Blood Pressure Control. Frontiers in Cardiovascular Medicine, 2021, 8, 754778.	2.4	14
14	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism, 2020, 32, 537-547.e3.	16.2	116
15	Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension, 2020, 76, 1104-1112.	2.7	118
16	NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity. Journal of the American Heart Association, 2020, 9, e016419.	3.7	11
17	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metabolism, 2020, 32, 176-187.e4.	16.2	400
18	Response by Zhang et al to Letter Regarding Article, â€œAssociation of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19â€• Circulation Research, 2020, 126, e142-e143.	4.5	79

#	Article	IF	Citations
19	Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. Hypertension, 2020, 76, e15-e17.	2.7	54
20	Longitudinal Association Between Markers of Liver Injury and Mortality in COVIDâ€19 in China. Hepatology, 2020, 72, 389-398.	7.3	346
21	Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism, 2020, 31, 1068-1077.e3.	16.2	1,207
22	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research, 2020, 126, 1671-1681.	4.5	948
23	Identification of Novel Alleles of the Rice Blast-Resistance Gene Pi9 through Sequence-Based Allele Mining. Rice, 2020, 13, 80.	4.0	11
24	No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World Journal of Clinical Cases, 2020, 8, 5576-5588.	0.8	26